FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2154841567> ?p ?o ?g. }

• W2154841567 endingPage "256" @default.
• W2154841567 startingPage "249" @default.
• W2154841567 abstract "Patients with melanoma harbouring Val600 BRAF mutations benefit from treatment with BRAF inhibitors. However, no targeted treatments exist for patients with BRAF wild-type tumours, including those with NRAS mutations. We aimed to assess the use of MEK162, a small-molecule MEK1/2 inhibitor, in patients with NRAS-mutated or Val600 BRAF-mutated advanced melanoma.In our open-label, non-randomised, phase 2 study, we assigned patients with NRAS-mutated or BRAF-mutated advanced melanoma to one of three treatment arms on the basis of mutation status. Patients were enrolled at university hospitals or private cancer centres in Europe and the USA. The three arms were: twice-daily MEK162 45 mg for NRAS-mutated melanoma, twice-daily MEK162 45 mg for BRAF-mutated melanoma, and twice-daily MEK162 60 mg for BRAF-mutated melanoma. Previous treatment with BRAF inhibitors was permitted, but previous MEK inhibitor therapy was not allowed. The primary endpoint was the proportion of patients who had an objective response (ie, a complete response or confirmed partial response). We report data for the 45 mg groups. We assessed clinical activity in all patients who received at least one dose of MEK162 and in patients assessable for response (with two available CT scans). This study is registered with ClinicalTrials.gov, number NCT01320085, and is currently recruiting additional patients with NRAS mutations (based on a protocol amendment).Between March 31, 2011, and Jan 17, 2012, we enrolled 71 patients who received at least one dose of MEK162 45 mg. By Feb 29, 2012 (data cutoff), median follow-up was 3·3 months (range 0·6-8·7; IQR 2·2-5·0). No patients had a complete response. Six (20%) of 30 patients with NRAS-mutated melanoma had a partial response (three confirmed) as did eight (20%) of 41 patients with BRAF-mutated melanoma (two confirmed). The most frequent adverse events were acneiform dermatitis (18 [60%] patients with NRAS -mutated melanoma and 15 [37%] patients with the BRAF-mutated melanoma), rash (six [20%] and 16 [39%]), peripheral oedema (ten [33%] and 14 [34%]), facial oedema (nine [30%] and seven [17%]), diarrhoea (eight [27%] and 15 [37%]), and creatine phosphokinase increases (11 [37%] and nine [22%]). Increased creatine phosphokinase was the most common grade 3-4 adverse event (seven [23%] and seven [17%]). Four patients had serious adverse events (two per arm), which included diarrhoea, dehydration, acneiform dermatitis, general physical deterioration, irregular heart rate, malaise, and small intestinal perforation. No deaths occurred from treatment-related causes.To our knowledge, MEK162 is the first targeted therapy to show activity in patients with NRAS -mutated melanoma and might offer a new option for a cancer with few effective treatments.Novartis Pharmaceuticals." @default.
• W2154841567 created "2016-06-24" @default.
• W2154841567 creator A5003887338 @default.
• W2154841567 creator A5005946442 @default.
• W2154841567 creator A5007871238 @default.
• W2154841567 creator A5015424908 @default.
• W2154841567 creator A5029398339 @default.
• W2154841567 creator A5032541182 @default.
• W2154841567 creator A5034365278 @default.
• W2154841567 creator A5044736874 @default.
• W2154841567 creator A5056473034 @default.
• W2154841567 creator A5056685282 @default.
• W2154841567 creator A5061683749 @default.
• W2154841567 creator A5068961742 @default.
• W2154841567 creator A5071929183 @default.
• W2154841567 creator A5088390068 @default.
• W2154841567 creator A5089297467 @default.
• W2154841567 date "2013-03-01" @default.
• W2154841567 modified "2023-10-11" @default.
• W2154841567 title "MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study" @default.
• W2154841567 cites W1499291662 @default.
• W2154841567 cites W1516437155 @default.
• W2154841567 cites W1545583410 @default.
• W2154841567 cites W1752845679 @default.
• W2154841567 cites W1917632054 @default.
• W2154841567 cites W1950572133 @default.
• W2154841567 cites W1977607846 @default.
• W2154841567 cites W1988379285 @default.
• W2154841567 cites W1989121777 @default.
• W2154841567 cites W1996707437 @default.
• W2154841567 cites W1997825389 @default.
• W2154841567 cites W2009642188 @default.
• W2154841567 cites W2026524381 @default.
• W2154841567 cites W2056199226 @default.
• W2154841567 cites W2060317877 @default.
• W2154841567 cites W2063392612 @default.
• W2154841567 cites W2064969209 @default.
• W2154841567 cites W2080686146 @default.
• W2154841567 cites W2086571195 @default.
• W2154841567 cites W2097995306 @default.
• W2154841567 cites W2106494998 @default.
• W2154841567 cites W2110478149 @default.
• W2154841567 cites W2128542677 @default.
• W2154841567 cites W2136474966 @default.
• W2154841567 cites W2141830999 @default.
• W2154841567 cites W2144096834 @default.
• W2154841567 cites W2153216846 @default.
• W2154841567 cites W2155777530 @default.
• W2154841567 cites W2156078931 @default.
• W2154841567 cites W2156266404 @default.
• W2154841567 cites W2166262263 @default.
• W2154841567 cites W2168143310 @default.
• W2154841567 cites W2330814896 @default.
• W2154841567 cites W2562120582 @default.
• W2154841567 cites W2998895464 @default.
• W2154841567 doi "https://doi.org/10.1016/s1470-2045(13)70024-x" @default.
• W2154841567 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23414587" @default.
• W2154841567 hasPublicationYear "2013" @default.
• W2154841567 type Work @default.
• W2154841567 sameAs 2154841567 @default.
• W2154841567 citedByCount "561" @default.
• W2154841567 countsByYear W21548415672012 @default.
• W2154841567 countsByYear W21548415672013 @default.
• W2154841567 countsByYear W21548415672014 @default.
• W2154841567 countsByYear W21548415672015 @default.
• W2154841567 countsByYear W21548415672016 @default.
• W2154841567 countsByYear W21548415672017 @default.
• W2154841567 countsByYear W21548415672018 @default.
• W2154841567 countsByYear W21548415672019 @default.
• W2154841567 countsByYear W21548415672020 @default.
• W2154841567 countsByYear W21548415672021 @default.
• W2154841567 countsByYear W21548415672022 @default.
• W2154841567 countsByYear W21548415672023 @default.
• W2154841567 crossrefType "journal-article" @default.
• W2154841567 hasAuthorship W2154841567A5003887338 @default.
• W2154841567 hasAuthorship W2154841567A5005946442 @default.
• W2154841567 hasAuthorship W2154841567A5007871238 @default.
• W2154841567 hasAuthorship W2154841567A5015424908 @default.
• W2154841567 hasAuthorship W2154841567A5029398339 @default.
• W2154841567 hasAuthorship W2154841567A5032541182 @default.
• W2154841567 hasAuthorship W2154841567A5034365278 @default.
• W2154841567 hasAuthorship W2154841567A5044736874 @default.
• W2154841567 hasAuthorship W2154841567A5056473034 @default.
• W2154841567 hasAuthorship W2154841567A5056685282 @default.
• W2154841567 hasAuthorship W2154841567A5061683749 @default.
• W2154841567 hasAuthorship W2154841567A5068961742 @default.
• W2154841567 hasAuthorship W2154841567A5071929183 @default.
• W2154841567 hasAuthorship W2154841567A5088390068 @default.
• W2154841567 hasAuthorship W2154841567A5089297467 @default.
• W2154841567 hasConcept C121608353 @default.
• W2154841567 hasConcept C126322002 @default.
• W2154841567 hasConcept C143998085 @default.
• W2154841567 hasConcept C184235292 @default.
• W2154841567 hasConcept C203092338 @default.
• W2154841567 hasConcept C21790070 @default.
• W2154841567 hasConcept C2777658100 @default.
• W2154841567 hasConcept C2781187634 @default.
• W2154841567 hasConcept C2781249067 @default.

• next